WUYAN PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO LTD

Overview

WUYAN PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO LTD is an active pharmaceutical ingredient (API) supplier with 6 active FDA Type II Drug Master Files, covering COREY 16; COREY 21; ERIBULIN INTERMIDIATE EA14; ERIBULIN INTERMIDIATE S5; THINNERTIDE; TIRZEPATIDE.

API / Drug Master Files

WUYAN PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO LTD holds 6 active (6 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• THINNERTIDEActive2025-03-19
• ERIBULIN INTERMIDIATE EA14Active2024-12-05
• ERIBULIN INTERMIDIATE S5Active2024-12-05
• TIRZEPATIDEActive2024-06-27
• COREY 16Active2024-06-05
• COREY 21Active2023-07-06

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to WUYAN PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.